153 related articles for article (PubMed ID: 36518085)
21. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
[TBL] [Abstract][Full Text] [Related]
23. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Crucitti C; Ingannato A; Bagnoli S; Padiglioni S; Galdo G; Emiliani F; Frigerio D; Moschini V; Morinelli C; Sorbi S; Bessi V; Nacmias B
J Neurol Sci; 2023 Oct; 453():120805. PubMed ID: 37716237
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J; Leuzy A; Karikari TK; Hye A; Benedet AL; Lantero-Rodriguez J; Mattsson-Carlgren N; Schöll M; Mecocci P; Vellas B; Tsolaki M; Kloszewska I; Soininen H; Lovestone S; Aarsland D; ; Hansson O; Rosa-Neto P; Westman E; Blennow K; Zetterberg H; Ashton NJ
Alzheimers Dement; 2021 Jul; 17(7):1145-1156. PubMed ID: 33491853
[TBL] [Abstract][Full Text] [Related]
25. Differential diagnosis of mild cognitive impairment of Alzheimer's disease by Simoa p-tau181 measurements with matching plasma and CSF.
Wu L; Arvai S; Wang SJ; Liu AJ; Xu B
Front Mol Neurosci; 2023; 16():1288930. PubMed ID: 38260807
[TBL] [Abstract][Full Text] [Related]
26. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
27. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
28. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.
Tatebe H; Kasai T; Ohmichi T; Kishi Y; Kakeya T; Waragai M; Kondo M; Allsop D; Tokuda T
Mol Neurodegener; 2017 Sep; 12(1):63. PubMed ID: 28866979
[TBL] [Abstract][Full Text] [Related]
29. Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study.
Wang YL; Chen J; Du ZL; Weng H; Zhang Y; Li R; Jia Z; Sun M; Jiang J; Wang FZ; Xu J;
Front Neurol; 2021; 12():695696. PubMed ID: 34557143
[No Abstract] [Full Text] [Related]
30. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias.
Cicognola C; Hansson O; Scheltens P; Kvartsberg H; Zetterberg H; Teunissen CE; Blennow K
Alzheimers Res Ther; 2021 Feb; 13(1):38. PubMed ID: 33557920
[TBL] [Abstract][Full Text] [Related]
31. Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF; Ashton NJ; Karikari TK; Strikwerda-Brown C; Köbe T; Gonneaud J; Pichet Binette A; Ozlen H; Yakoub Y; Simrén J; Pannee J; Lantero-Rodriguez J; Labonté A; Baker SL; Schöll M; Vanmechelen E; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
Ann Neurol; 2022 Apr; 91(4):548-560. PubMed ID: 35084051
[TBL] [Abstract][Full Text] [Related]
32. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.
Tsiknia AA; Sundermann EE; Reas ET; Edland SD; Brewer JB; Galasko D; Banks SJ;
Alzheimers Res Ther; 2022 Nov; 14(1):160. PubMed ID: 36324151
[TBL] [Abstract][Full Text] [Related]
33. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
34. Plasma p-tau181/Aβ
Fowler CJ; Stoops E; Rainey-Smith SR; Vanmechelen E; Vanbrabant J; Dewit N; Mauroo K; Maruff P; Rowe CC; Fripp J; Li QX; Bourgeat P; Collins SJ; Martins RN; Masters CL; Doecke JD
Alzheimers Dement (Amst); 2022; 14(1):e12375. PubMed ID: 36447478
[TBL] [Abstract][Full Text] [Related]
35. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
[TBL] [Abstract][Full Text] [Related]
36. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
37. Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease.
Ghahremani M; Wang M; Chen HY; Zetterberg H; Smith E; Ismail Z;
Neurology; 2023 Feb; 100(7):e683-e693. PubMed ID: 36323521
[TBL] [Abstract][Full Text] [Related]
38. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
39. Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy.
Morrison MS; Aparicio HJ; Blennow K; Zetterberg H; Ashton NJ; Karikari TK; Tripodis Y; Martin B; Palmisano JN; Sugarman MA; Frank B; Steinberg EG; Turk KW; Budson AE; Au R; Goldstein LE; Jun GR; Kowall NW; Killiany R; Qiu WQ; Stern RA; Mez J; McKee AC; Stein TD; Alosco ML
Brain; 2022 Oct; 145(10):3546-3557. PubMed ID: 35554506
[TBL] [Abstract][Full Text] [Related]
40. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
